MA40910A - Poudres de rapamycine pour administration pulmonaire - Google Patents

Poudres de rapamycine pour administration pulmonaire

Info

Publication number
MA40910A
MA40910A MA040910A MA40910A MA40910A MA 40910 A MA40910 A MA 40910A MA 040910 A MA040910 A MA 040910A MA 40910 A MA40910 A MA 40910A MA 40910 A MA40910 A MA 40910A
Authority
MA
Morocco
Prior art keywords
rapamycin
powders
pulmonary administration
pulmonary
administration
Prior art date
Application number
MA040910A
Other languages
English (en)
Inventor
Abhijit Kamerkar
Michael M Lipp
Original Assignee
Civitas Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Civitas Therapeutics Inc filed Critical Civitas Therapeutics Inc
Publication of MA40910A publication Critical patent/MA40910A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA040910A 2014-11-07 2015-11-05 Poudres de rapamycine pour administration pulmonaire MA40910A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462076651P 2014-11-07 2014-11-07

Publications (1)

Publication Number Publication Date
MA40910A true MA40910A (fr) 2017-09-12

Family

ID=54697649

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040910A MA40910A (fr) 2014-11-07 2015-11-05 Poudres de rapamycine pour administration pulmonaire

Country Status (8)

Country Link
US (1) US9387169B2 (fr)
EP (1) EP3215121B1 (fr)
JP (2) JP2017533212A (fr)
AU (2) AU2015342919B2 (fr)
CA (1) CA2966637C (fr)
ES (1) ES3022184T3 (fr)
MA (1) MA40910A (fr)
WO (1) WO2016073836A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6529012B2 (ja) 2013-10-08 2019-06-12 エイアイ・セラピューティクス・インコーポレーテッド リンパ脈管筋腫症の処置のためのラパマイシン
NZ724756A (en) 2014-04-04 2023-07-28 Ai Therapeutics Inc An inhalable rapamycin formulation for treating age-related conditions
AU2015330905B2 (en) * 2014-10-07 2021-02-25 AI Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
PT3429580T (pt) * 2016-03-16 2025-08-12 Buzzelet Development And Technologies Ltd Composição de canabinoides enriquecida em terpenos
US20200230115A1 (en) * 2017-07-24 2020-07-23 University Of Cincinnati Methods of treating influenza-associated viral pneumonia
US11878023B2 (en) 2017-10-25 2024-01-23 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for delivering pharmaceutical agents

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US5080899A (en) 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5635161A (en) 1995-06-07 1997-06-03 Abbott Laboratories Aerosol drug formulations containing vegetable oils
FR2736550B1 (fr) 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
GB9606452D0 (en) 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
US20020052310A1 (en) 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6503480B1 (en) 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6652837B1 (en) 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
BR9713661A (pt) 1996-12-30 2000-10-24 Battelle Memorial Institute Formulação e método para o tratamento de neoplasmas por inalação
US6451784B1 (en) 1996-12-30 2002-09-17 Battellepharma, Inc. Formulation and method for treating neoplasms by inhalation
ES2236832T3 (es) 1997-01-16 2005-07-16 Massachusetts Institute Of Technology Preparacion de particulas para inhalacion.
US5989591A (en) 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US20040039047A1 (en) 1998-08-11 2004-02-26 Mark Zamoyski Compositions and methods for treating lung cancers
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6586008B1 (en) 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
US7252840B1 (en) 1999-08-25 2007-08-07 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles
PT1913939T (pt) * 2000-06-27 2017-07-19 Vectura Ltd Formulações para utilização em dispositivos inalatórios
US20040018228A1 (en) 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
JP2005504715A (ja) 2000-12-29 2005-02-17 アドバンスト インハレーション リサーチ，インコーポレイテッド 持続放出特性を有する吸入用粒子
US6766799B2 (en) 2001-04-16 2004-07-27 Advanced Inhalation Research, Inc. Inhalation device
US6848197B2 (en) 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
CA2457148A1 (fr) 2001-08-20 2003-02-27 Transave, Inc. Traitement du cancer par inhalation de formulations stables contenant platine
CA2456746A1 (fr) 2001-08-20 2003-02-27 Transave, Inc. Procede destine a traiter des cancers du poumon
US20030166509A1 (en) 2001-11-20 2003-09-04 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery and methods of use thereof
JP4368198B2 (ja) 2001-11-20 2009-11-18 アルカーメス，インコーポレイテッド 肺送達用の改良された粒状組成物
ES2718455T3 (es) * 2002-03-20 2019-07-02 Civitas Therapeutics Inc Formulaciones terapéuticas sostenidas inhalables
HUE031167T2 (hu) 2002-03-20 2017-07-28 Civitas Therapeutics Inc A levodopa pulmonális bejuttatása
ATE394136T1 (de) 2002-03-20 2008-05-15 Alkermes Inc Inhalationsgerät für pulverförmige substanzen
US7754242B2 (en) 2002-03-20 2010-07-13 Alkermes, Inc. Inhalable sustained therapeutic formulations
US7008644B2 (en) 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
CA2486622A1 (fr) 2002-05-20 2003-12-04 Research Development Foundation Medicament de type aerosol pour l'inhibition de metastases pulmonaires
DK1531794T3 (en) 2002-06-28 2017-08-28 Civitas Therapeutics Inc INHALABLE EPINEPHRIN
US7763280B2 (en) 2002-11-28 2010-07-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing powder formulation for inhalation
US20050119330A1 (en) 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
JP2007517537A (ja) 2003-06-13 2007-07-05 アドバンスト インハレーション リサーチ，インコーポレイテッド 吸入用低投薬量医薬粉末
AR050374A1 (es) 2004-08-20 2006-10-18 Wyeth Corp Forma polimorfica de rafampicina
US20060094744A1 (en) 2004-09-29 2006-05-04 Maryanoff Cynthia A Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
JP2008532953A (ja) 2005-03-08 2008-08-21 ライフサイクル ファーマ エー／エス シロリムスおよび／またはその類縁物質を含む医薬組成物
AU2006227623B2 (en) 2005-03-17 2011-10-20 Elan Pharma International Limited Injectable compositions of nanoparticulate immunosuppressive compounds
EP1962819A1 (fr) 2005-12-20 2008-09-03 Wyeth Maitrise de la stabilite de la forme pharmaceutique de cci-779 par l'elimination optimale des impuretes de la substance medicamenteuse
PT1983984T (pt) 2006-02-02 2018-06-14 Novartis Ag Tratamento da esclerosa tuberosa
RU2010104916A (ru) 2006-08-16 2011-08-20 Михаил В. Благосклонный (US) Способ профилактики и лечения возрастных заболеваний
US20080063722A1 (en) 2006-09-08 2008-03-13 Advanced Inhalation Research, Inc. Composition of a Spray-Dried Powder for Pulmonary Delivery of a Long Acting Neuraminidase Inhibitor (LANI)
EP2241342A3 (fr) 2006-11-20 2011-01-12 Lutonix, Inc. Revêtements de libération de médicament pour dispositifs médicaux
EP1952807A1 (fr) 2007-01-24 2008-08-06 LEK Pharmaceuticals D.D. Formulation de Sirolimus
US20100166869A1 (en) * 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension
WO2008156586A2 (fr) 2007-06-12 2008-12-24 Alkermes, Inc. Perfectionnements à des dispositifs inhalateurs de poudre
WO2009026434A1 (fr) 2007-08-21 2009-02-26 Alkermes, Inc. Formulations pharmaceutiques pulmonaires
GB0908129D0 (en) * 2009-05-12 2009-06-24 Innovata Ltd Composition
US20120076838A1 (en) * 2009-05-27 2012-03-29 Samyang Biopharmaceuticals Corporation Poorly soluble drug containing microsphere with improved bioavailabilty and method of preparing the same
US9248110B2 (en) 2010-03-18 2016-02-02 Steven Lehrer Compositions and methods of treating and preventing lung cancer and lymphangioleiomyomatosis
PT105058B (pt) 2010-04-21 2013-04-17 Hovione Farmaciencia S A Processo para processamento de partículas de ingredientes activos farmacêuticos
WO2011163600A2 (fr) 2010-06-25 2011-12-29 Apt Pharmaceuticals, Inc. Compositions de tacrolimus pour administration par aérosol
WO2014074797A1 (fr) * 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Poudres pulmonaires de densité ultra basse
US8545878B1 (en) * 2012-11-09 2013-10-01 Civitas Therapeutics, Inc. Capsules containing high doses of levodopa for pulmonary use
JP6529012B2 (ja) * 2013-10-08 2019-06-12 エイアイ・セラピューティクス・インコーポレーテッド リンパ脈管筋腫症の処置のためのラパマイシン
MX2016010373A (es) * 2014-02-11 2016-11-30 Lam Therapeutics Inc Rapamicina para el tratamiento de linfangioleiomiomatosis.
NZ724756A (en) * 2014-04-04 2023-07-28 Ai Therapeutics Inc An inhalable rapamycin formulation for treating age-related conditions

Also Published As

Publication number Publication date
JP7277490B2 (ja) 2023-05-19
AU2015342919A1 (en) 2017-05-18
JP2017533212A (ja) 2017-11-09
CA2966637A1 (fr) 2016-05-12
JP2021054870A (ja) 2021-04-08
ES3022184T3 (en) 2025-05-28
EP3215121A1 (fr) 2017-09-13
CA2966637C (fr) 2024-02-13
US20160128936A1 (en) 2016-05-12
AU2020250195B2 (en) 2022-06-02
NZ731431A (en) 2024-07-05
WO2016073836A1 (fr) 2016-05-12
AU2020250195A1 (en) 2020-11-05
EP3215121B1 (fr) 2025-02-26
US9387169B2 (en) 2016-07-12
AU2015342919B2 (en) 2020-07-23
EP3215121C0 (fr) 2025-02-26

Similar Documents

Publication Publication Date Title
SG11201706123XA (en) Pharmaceutical compositions comprising meloxicam
MA41265A (fr) Compositions pour administration de médicaments iléo-jéjunal.
GB201419257D0 (en) Pharmaceutical compositions
GB201618482D0 (en) Pharmaceutical compositions
GB201409471D0 (en) Pharmaceutical composition
IL249553A0 (en) Pharmaceutical preparations
GB201409488D0 (en) Pharmaceutical composition
GB201409485D0 (en) Pharmaceutical composition
GB201521462D0 (en) Pharmaceutical composition
DK3191085T3 (da) Misbrugsresistente farmaceutiske sammensætninger
IL251337A0 (en) Pharmaceutical preparations with long-term activity
SG11201705543VA (en) Sulfonamide pharmaceutical composition
EP3215121C0 (fr) Poudres de rapamycine pour l'administration pulmonaire
ZA201508726B (en) Pharmaceutical composition
ZA201502073B (en) Pharmaceutical composition
IL255510A (en) Pharmaceutical compositions
SMT201900438T1 (it) Nuovi derivati di cyp-eicosanoide
IL250817A0 (en) pharmaceutical preparations
GB201515310D0 (en) Pharmaceutical composition
HUE066250T2 (hu) Pimobendánt tartalmazó gyógyszerkészítmény
GB201520862D0 (en) Pharmaceutical composition
LT3089740T (lt) Farmacinė kompozicija
SG11201608123VA (en) Pharmaceutical composition for external use
SG10201504332VA (en) Pharmaceutical Composition
PL3160263T3 (pl) Kompozycje do zapobiegania zakażeniom